## Supplemental File 3 - Schedule of Assessments

Week	0	1	2			3		4		8*	12	24
Visit Number	1	2	3	4	5	6	7	8	<b>5</b> 9	10	11	12
Day	0	1	5/6	7	12/13	14	19/20	21	28	56	84	168
Intervention		CBT 1	KET 1	CBT 2	KET 2		KET 3	CBT 4				
Informed Consent	х											
MINI <sup>a</sup>	х											
C-SSRS-6	х											
Medical assessment	х											
Concomitant	х		х		х		х		х	х	х	х
Medications												
Other Psychological care	х		х		х		х		х	х	х	х
Height, weight	х		х		х		х					
Vital signs <sup>b</sup>	х		x <sup>0, 15, 60,</sup>		x <sup>0, 15,</sup>		x <sup>0, 15,</sup>		x	х	х	х
	X		120		60, 120		60, 120		~	~	, A	
POC – Urine Drug Screen <sup>c</sup>	х		XPRE		XPRE		XPRE		х	х	х	х
Urinary Hcg (if applicable)	X		xPRE		XPRE		XPRE		x	x	x	x
Eligibility	х											
Demographics	х											
SURGE	х											
WURS	X											<u> </u>
TLFB - MA	X		x		х		х		х	х	х	х
VAS-C for MA	X		x		x		x		x	x	x	x
AWQ	x		~		~		~		x	x	x	x
WHOQOL-BREF	x								x	x	x	x
TSQM-II	X								x	x		
CSQ-8									x	x		
Medical Review			x		х		х		~	x		
Adverse Events		x	x	х	x	x	x	х	x	x	х	х
C-SSRS-SLV		~	x		x	~	x	~	x	x	x	x
TLFB – ketamine	х		x		x		x		x	x	x	x
TLFB – other substances	x		~		~				x	x	x	x
VAS-C for Ketamine	x		x		х		х		x	x	x	x
	~	-	x <sup>60, 120</sup>		x <sup>60,</sup>		x <sup>60,</sup>		~	~	~	-
KSET – acute treatment			X		X 120		120 X					
YMRS			X <sup>PRE,POST</sup>		<b>x</b> <sup>POST</sup>		<b>x</b> <sup>POST</sup>					
CADSS-6			XPOST		x <sup>POST</sup>		x <sup>POST</sup>					<u> </u>
DEQ-5			x <sup>POST</sup>		x <sup>POST</sup>		x <sup>POST</sup>					
			x x <sup>POST</sup>		x x <sup>POST</sup>		x x <sup>POST</sup>					
HMS PHQ-9	v		^		^		^		v	v	v	x
GAD-7	X								X	X	X	
DERS	x x								x x	x x	x x	x x
ISI												
SUSI	X	+							X	X	X	X
	X							XPRE	х	X	X	X
Emotional N-back task	X							x <sup>PRE</sup>				├
Emotional Stroop	х							X		<u> </u>		<u> </u>
Qualitative Interview <sup>d</sup> *Primary Endpoint <b>AWQ</b> Amphet	amina Wi	thdrawal	Questionn		SS & Clini	l isian Adn	l		-	X		

\*Primary Endpoint AWQ Amphetamine Withdrawal Questionnaire CADSS-6 Clinician Administered Dissociation States Scales C-SSRS Columbia-Suicide Severity Rating Scale C-SSRS Columbia-Suicide Severity Rating Scale – Since Last Visit CSQ-8 Client Satisfaction Questionnaire DERS Difficulties in Emotion Regulation Scale DEQ-5 Drug Effects Questionnaire GAD-7 Generalised Anxiety Disorder Scale-7 HMS Hood Mysticism Scale ISI Insomnia Severity Index KSET Ketamine Side Effect Tool MA Methamphetamine MINI Mini-International Neuropsychiatric Interview PHQ-9 Patient Health Questionnaire POC Point of Care SURGE Substance Use Goals and Expectations SUSI Substance Use & Sex Index TLFB Timeline Follow-Back TSQM-II Treatment Satisfaction Questionnaire for Medication VAS-C Visual Analogue Scale – Craving WURS Wender-Utah Rating Scale WHOQOL-BREF World Health Organisation Quality of Life Brief Version YMRS Young Mania Rating Scale

(a) MINI modules A (major depressive disorder), C (bipolar disorder), I and J (alcohol and substance use disorders), K (current psychotic disorder), 0 (rule out medical, organic or drug causes), (b) Blood pressure, heart rate, oxygen saturations, respiratory rate (c) POC also considered a measure of efficacy (d) Qualitative interviews (optional) will be conducted during Week 5 to Week 8.